TECH — BIO-TECHNE Corp
—
Nasdaq ·
Health Care ·
Biotechnology ·
CIK 842023 ·
Last close
$47.97
Market Cap
$7.51B
52W High
$62.35
52W Low
$43.12
ADV30
2,958,942
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Mar 2026 | — | — | — | — | — | — | — |
| Dec 2025 | 295,877,000 | 191,277,000 | 54,461,000 | 38,009,000 | 2,522,699,000 | 172,879,000 | 511,710,000 |
| Sep 2025 | 286,555,000 | 188,112,000 | 47,658,000 | 38,185,000 | 2,526,148,000 | 144,962,000 | 560,334,000 |
| Jun 2025 | 316,964,000 | 198,812,000 | 116,689,000 | -17,678,000 | 2,557,868,000 | 162,186,000 | 639,060,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$249,317,000
Investing CF
$-13,783,000
Financing CF
$-251,687,000
CapEx
$-26,297,000
Dividends Paid
$-49,881,000
Buybacks
$-200,127,000
EPS Diluted TTM
$0.69
As of
2026-05-10
Balance + Analyst (yfinance extras)
Retained Earnings
$1,106,819,000
Inventory
$205,447,000
Receivables
$184,614,000
ST Investments
—
EBIT TTM
$83,199,000
Pretax Income TTM
$75,916,000
Interest Exp TTM
$7,283,000
Analysts
11
Yahoo Snapshot (yfinance, live)
Total Revenue
$1,210,811,008
EBITDA
$366,044,992
Free Cash Flow
$299,849,376
Enterprise Value
$7,624,387,584
Total Cash
$214,114,000
Total Debt
$290,321,984
Shares Out
156,568,751
Trailing EPS
$0.70
Book Value
$12.90
ROE
5.3%
ROA
7.5%
Div Yield
0.66%
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Jun 2025 | 1,219,635,000 | 242,804,000 | 73,400,000 | 2,557,868,000 | 639,060,000 | — | 287,556,000 |
| Jun 2024 | 1,159,060,000 | 246,401,000 | 168,105,000 | 2,703,867,000 | 635,017,000 | — | 298,981,000 |
| Jun 2023 | 1,136,702,000 | 290,998,000 | 285,263,000 | 2,638,692,000 | 672,176,000 | — | 254,393,000 |
| Jun 2022 | 1,105,599,000 | 295,828,000 | 272,051,000 | 2,294,805,000 | 593,794,000 | — | 325,272,000 |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$2.06
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| QGEN | QIAGEN N.V. | $7.33B | $35.54 | — |
| PCVX | Vaxcyte, Inc. | $7.24B | $50.11 | — |
| IMVT | Immunovant, Inc. | $6.95B | $33.83 | — |
| HALO | HALOZYME THERAPEUTICS, INC. | $8.15B | $68.72 | — |
| IBRX | ImmunityBio, Inc. | $8.30B | $7.92 | — |
News headlines (Yahoo Finance, 1h cache)
Are Wall Street Analysts Bullish on Bio-Techne Stock?
2026-05-25 18:23 · Yahoo
2 Healthcare Stocks to Research Further and 1 We Find Risky
2026-05-23 11:08 · Yahoo
The 5 Most Interesting Analyst Questions From Bio-Techne’s Q1 Earnings Call
2026-05-16 22:52 · Yahoo
Baron Asset Fund Sold Bio-Techne Corporation (TECH) Due to Concerns Over Potential Impact of AI
2026-05-14 14:42 · Yahoo
1 Cash-Producing Stock Worth Investigating and 2 We Turn Down
2026-05-14 01:40 · Yahoo
There May Be Some Bright Spots In Bio-Techne's (NASDAQ:TECH) Earnings
2026-05-13 13:08 · Yahoo
Investment Firm Sells $12.2 Million Worth of Materials Stock, According to Latest SEC Filing
2026-05-12 13:21 · Yahoo
Bio-Techne Q3 Earnings Call Highlights
2026-05-07 06:07 · Yahoo
Why Bio-Techne (TECH) Is Up 5.9% After Profits Rose Despite Slightly Lower Sales – And What's Next
2026-05-06 22:13 · Yahoo
Bio-Techne Corporation Q3 2026 Earnings Call Summary
2026-05-06 20:57 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.